Guggenheim Maintains Buy on Blueprint Medicines, Raises Price Target to $82
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Michael Schmidt maintains a Buy rating on Blueprint Medicines (NASDAQ:BPMC) and raises the price target from $78 to $82.
May 23, 2023 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guggenheim analyst Michael Schmidt maintains a Buy rating on Blueprint Medicines and raises the price target from $78 to $82.
The raised price target by Guggenheim analyst Michael Schmidt indicates a positive outlook for Blueprint Medicines. This news is likely to have a positive impact on the stock price in the short term as it shows increased confidence in the company's performance and potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100